StemoniX is empowering the discovery of new medicines to treat challenging diseases via the world's first ready-to-use assay plates containing living human microOrgans®, including electrophysiologically active neural (microBrain®) and cardiac (microHeart®) cells. Predictive, accurate, and consistent, StemoniX's products enable pharmaceutical scientists to quickly and economically conduct high-throughput screening in a simplified workflow. Through their Discovery as a Service branch, the company also partners with organizations to screen compounds as well as create customized microOrgan models and assays tailored to individual discovery and toxicity needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/19 | $14,400,000 | Series B |
Alumni Ventures Group Brightstone Capital  Crescent Ridge Partners Ventures Keshif Ventures Mayo Clinic Seed San Diego | undisclosed |
